



REPORTED SALES vs. PRIOR PERIOD

SMM

	FOURTH QUARTER					TWELVE MONTHS				
	2008	2007	% Change			2008	2007	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT (2) (3)										
<u>ACIPHEX/PARIET</u>										
US	140	166	-15.7%	-15.7%	-	539	645	-16.4%	-16.4%	-
Intl	134	181	-26.0%	-15.5%	-10.5%	619	712	-13.1%	-16.6%	3.5%
WW	274	347	-21.0%	-15.6%	-5.4%	1,158	1,357	-14.7%	-16.6%	1.9%
<u>CONCERTA</u>										
US	208	222	-6.3%	-6.3%	-	830	798	4.0%	4.0%	-
Intl	72	67	7.5%	34.3%	-26.8%	417	230	81.3%	77.4%	3.9%
WW	280	289	-3.1%	3.1%	-6.2%	1,247	1,028	21.3%	20.4%	0.9%
<u>DURAGESIC/FENTANYL TRANSDERMAL</u>										
US	72	72	0.0%	0.0%	-	271	391	-30.7%	-30.7%	-
Intl	200	192	4.2%	10.4%	-6.2%	765	773	-1.0%	-6.3%	5.3%
WW	272	264	3.0%	7.5%	-4.5%	1,036	1,164	-11.0%	-14.5%	3.5%
<u>LEVAQUIN/FLOXIN</u>										
US	393	409	-3.9%	-3.9%	-	1,510	1,564	-3.5%	-3.5%	-
Intl	18	23	-21.7%	-7.7%	-14.0%	81	82	-1.2%	-1.0%	-0.2%
WW	411	432	-4.9%	-4.2%	-0.7%	1,591	1,646	-3.3%	-3.3%	0.0%
<u>PROCRI/EPREX</u>										
US	318	331	-3.9%	-3.9%	-	1,332	1,690	-21.2%	-21.2%	-
Intl	242	297	-18.5%	-8.2%	-10.3%	1,128	1,195	-5.6%	-10.5%	4.9%
WW	560	628	-10.8%	-5.9%	-4.9%	2,460	2,885	-14.7%	-16.7%	2.0%
<u>RAZADYNE/REMINYL</u>										
US	11	49	-77.6%	-77.6%	-	134	194	-30.9%	-30.9%	-
Intl	91	92	-1.1%	12.1%	-13.2%	407	337	20.8%	15.1%	5.7%
WW	102	141	-27.7%	-19.1%	-8.6%	541	531	1.9%	-1.7%	3.6%
<u>REMICADE</u>										
US	672	661	1.7%	1.7%	-	2,810	2,534	10.9%	10.9%	-
US Exports ⁽⁴⁾	209	246	-15.0%	-15.0%	-	927	792	17.0%	17.0%	-
Intl	5	1	400.0%	385.4%	14.6%	11	1	1000.0%	976.8%	23.2%
WW	886	908	-2.4%	-2.4%	-	3,748	3,327	12.7%	12.7%	-
<u>RISPERDAL/RISPERIDONE</u>										
US	91	570	-84.0%	-84.0%	-	1,287	2,198	-41.4%	-41.4%	-
Intl	194	304	-36.2%	-33.6%	-2.6%	839	1,222	-31.3%	-35.6%	4.3%
WW	285	874	-67.4%	-66.5%	-0.9%	2,126	3,420	-37.8%	-39.3%	1.5%
<u>RISPERDAL CONSTA</u>										
US	117	108	8.3%	8.3%	-	456	422	8.1%	8.1%	-
Intl	202	187	8.0%	20.9%	-12.9%	853	706	20.8%	15.2%	5.6%
WW	319	295	8.1%	16.3%	-8.2%	1,309	1,128	16.0%	12.5%	3.5%
<u>TOPAMAX</u>										
US	576	535	7.7%	7.7%	-	2,250	2,006	12.2%	12.2%	-
Intl	104	117	-11.1%	0.9%	-12.0%	481	447	7.6%	3.4%	4.2%
WW	680	652	4.3%	6.4%	-2.1%	2,731	2,453	11.3%	10.5%	0.8%
<u>VELCADE</u>										
US	-	3	-100.0%	-100.0%	-	4	8	-50.0%	-50.0%	-
Intl	208	162	28.4%	35.9%	-7.5%	783	526	48.9%	42.1%	6.8%
WW	208	165	26.1%	33.5%	-7.4%	787	534	47.4%	40.7%	6.7%
<u>OTHER</u>										
US	623	572	8.9%	8.9%	-	2,481	2,361	5.1%	5.1%	-
Intl	785	830	-5.4%	3.2%	-8.6%	3,352	3,032	10.6%	4.0%	6.6%
WW	1,408	1,402	0.4%	5.5%	-5.1%	5,833	5,393	8.2%	4.5%	3.7%
<u>TOTAL PHARMACEUTICAL</u>										
US	3,430	3,944	-13.0%	-13.0%	-	14,831	15,603	-4.9%	-4.9%	-
Intl	2,255	2,453	-8.1%	0.5%	-8.6%	9,736	9,263	5.1%	0.1%	5.0%
WW	5,685	6,397	-11.1%	-7.8%	-3.3%	24,567	24,866	-1.2%	-3.1%	1.9%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

(4) For external purposes, reported as U.S. sales



REPORTED SALES vs. PRIOR PERIOD

SMM

	FOURTH QUARTER					TWELVE MONTHS				
	2008	2007	% Change			2008	2007	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS ^{(2) (3)}										
<u>CORDIS</u> ⁽⁴⁾										
US	253	394	-35.8%	-35.8%	-	1,235	1,588	-22.2%	-22.2%	-
Intl	469	474	-1.1%	1.3%	-2.4%	1,900	1,837	3.4%	-3.1%	6.5%
WW	722	868	-16.8%	-15.5%	-1.3%	3,135	3,425	-8.5%	-12.0%	3.5%
<u>DEPUY</u>										
US	727	661	10.0%	10.0%	-	2,803	2,638	6.3%	6.3%	-
Intl	525	548	-4.2%	6.2%	-10.4%	2,186	1,949	12.2%	8.3%	3.9%
WW	1,252	1,209	3.6%	8.3%	-4.7%	4,989	4,587	8.8%	7.1%	1.7%
<u>DIABETES CARE</u>										
US	275	337	-18.4%	-18.4%	-	1,265	1,260	0.4%	0.4%	-
Intl	304	306	-0.7%	7.5%	-8.2%	1,270	1,113	14.1%	7.8%	6.3%
WW	579	643	-10.0%	-6.1%	-3.9%	2,535	2,373	6.8%	3.9%	2.9%
<u>ETHICON ENDO-SURGERY</u>										
US	515	481	7.1%	7.1%	-	1,901	1,792	6.1%	6.1%	-
Intl	602	583	3.3%	11.6%	-8.3%	2,385	2,042	16.8%	11.3%	5.5%
WW	1,117	1,064	5.0%	9.0%	-4.0%	4,286	3,834	11.8%	8.8%	3.0%
<u>ETHICON</u> ⁽⁵⁾										
US	363	353	2.8%	2.8%	-	1,450	1,399	3.6%	3.6%	-
Intl	555	591	-6.1%	3.5%	-9.6%	2,390	2,204	8.4%	4.0%	4.4%
WW	918	944	-2.8%	3.3%	-6.1%	3,840	3,603	6.6%	3.9%	2.7%
<u>ORTHO-CLINICAL DIAGNOSTICS</u> ⁽⁵⁾										
US	248	245	1.2%	1.2%	-	997	944	5.6%	5.6%	-
Intl	204	211	-3.3%	2.3%	-5.6%	844	761	10.9%	5.0%	5.9%
WW	452	456	-0.9%	1.7%	-2.6%	1,841	1,705	8.0%	5.4%	2.6%
<u>VISION CARE</u>										
US	201	190	5.8%	5.8%	-	890	812	9.6%	9.6%	-
Intl	401	376	6.6%	5.5%	1.1%	1,610	1,397	15.2%	8.0%	7.2%
WW	602	566	6.4%	5.7%	0.7%	2,500	2,209	13.2%	8.6%	4.6%
<u>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</u>										
US	2,582	2,661	-3.0%	-3.0%	-	10,541	10,433	1.0%	1.0%	-
Intl	3,060	3,089	-0.9%	5.6%	-6.5%	12,585	11,303	11.3%	5.8%	5.5%
WW	5,642	5,750	-1.9%	1.6%	-3.5%	23,126	21,736	6.4%	3.5%	2.9%

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)

⁽³⁾ Prior year amounts have been reclassified to conform with current presentation

⁽⁴⁾ Includes sales of Drug-Eluting Stents for Q4 2008 of \$70, \$202 and \$272 million Domestic, International and Worldwide respectively
 Includes sales of Drug-Eluting Stents for Q4 2007 of \$189, \$225 and \$414 million Domestic, International and Worldwide respectively
 Includes sales of Drug-Eluting Stents for Dec YTD 2008 of \$503, \$852 and \$1,355 million Domestic, International and Worldwide respectively
 Includes sales of Drug-Eluting Stents for Dec YTD 2007 of \$818, \$943 and \$1,761 million Domestic, International and Worldwide respectively

⁽⁵⁾ Prior year amounts include sales previously reported as "other"



REPORTED SALES vs. PRIOR PERIOD

SMM

CONSUMER SEGMENT (2)

SKIN CARE

	FOURTH QUARTER					TWELVE MONTHS				
	2008	2007	% Change			2008	2007	% Change		
Reported			Operational (1)	Currency	Reported			Operational (1)	Currency	
US	343	323	6.2%	6.2%	-	1,462	1,329	10.0%	10.0%	-
Intl	501	470	6.6%	15.3%	-8.7%	1,919	1,722	11.4%	6.7%	4.7%
WW	844	793	6.4%	11.5%	-5.1%	3,381	3,051	10.8%	8.1%	2.7%

BABY CARE

US	109	116	-6.0%	-6.0%	-	449	444	1.1%	1.1%	-
Intl	414	421	-1.7%	5.7%	-7.4%	1,765	1,538	14.8%	10.1%	4.7%
WW	523	537	-2.6%	3.2%	-5.8%	2,214	1,982	11.7%	8.0%	3.7%

ORAL CARE

US	192	189	1.6%	1.6%	-	780	789	-1.1%	-1.1%	-
Intl	204	190	7.4%	19.3%	-11.9%	844	699	20.7%	17.1%	3.6%
WW	396	379	4.5%	10.5%	-6.0%	1,624	1,488	9.1%	7.4%	1.7%

OTC/NUTRITIONALS

US	762	728	4.7%	4.7%	-	3,061	2,620	16.8%	16.8%	-
Intl	694	687	1.0%	12.6%	-11.6%	2,833	2,522	12.3%	8.2%	4.1%
WW	1,456	1,415	2.9%	8.5%	-5.6%	5,894	5,142	14.6%	12.6%	2.0%

WOMEN'S HEALTH

US	148	148	0.0%	0.0%	-	618	623	-0.8%	-0.8%	-
Intl	288	313	-8.0%	1.6%	-9.6%	1,293	1,183	9.3%	4.1%	5.2%
WW	436	461	-5.4%	1.1%	-6.5%	1,911	1,806	5.8%	2.4%	3.4%

WOUND CARE / OTHER

US	101	122	-17.2%	-17.2%	-	567	603	-6.0%	-6.0%	-
Intl	99	103	-3.9%	7.0%	-10.9%	463	421	10.0%	4.8%	5.2%
WW	200	225	-11.1%	-6.1%	-5.0%	1,030	1,024	0.6%	-1.5%	2.1%

TOTAL CONSUMER

US	1,655	1,626	1.8%	1.8%	-	6,937	6,408	8.3%	8.3%	-
Intl	2,200	2,184	0.7%	10.6%	-9.9%	9,117	8,085	12.8%	8.3%	4.5%
WW	3,855	3,810	1.2%	6.9%	-5.7%	16,054	14,493	10.8%	8.3%	2.5%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)